Neoadjuvant Chemotherapy and Nodal Response Rates in Luminal Breast Cancer: Effects of Age and Tumor Ki67

Judy C. Boughey; Tanya L. Hoskin; Matthew P. Goetz

doi:10.1245/s10434-022-11871-z

journal article May 15, 2022

Neoadjuvant Chemotherapy and Nodal Response Rates in Luminal Breast Cancer: Effects of Age and Tumor Ki67

Judy C. Boughey

Tanya L. Hoskin Matthew P. Goetz

Annals of Surgical Oncology Vol. 29 No. 9 pp. 5747-5756 · Springer Science and Business Media LLC

View at Publisher Save 10.1245/s10434-022-11871-z

Topics

No keywords indexed for this article. Browse by subject →

References

16

[1]

Murphy BL, Day CN, Hoskin TL, Habermann EB, Boughey JC. Neoadjuvant chemotherapy use in breast cancer is greatest in excellent responders: triple-negative and HER2+ subtypes. Ann Surg Oncol. 2018;25(8):2241–8. 10.1245/s10434-018-6531-5

[2]

Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients

Christina Yau, Marie Osdoit, Marieke van der Noordaa et al.

The Lancet Oncology 2022 10.1016/s1470-2045(21)00589-1

[3]

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

Patricia Cortazar, Lijun Zhang, Michael Untch et al.

The Lancet 2014 10.1016/s0140-6736(13)62422-8

[4]

Boughey JC, McCall LM, Ballman KV, et al. Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) prospective multicenter clinical trial. Ann Surg. 2014;260(4):608–14 (discussion 614-6). 10.1097/sla.0000000000000924

[5]

Harbeck N, Rastogi P, Martin M, et al. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the MonarchE study. Ann Oncol. 2021;32(12):1571–81. 10.1016/j.annonc.2021.09.015

[6]

Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr. 2001;30:96–102. 10.1093/oxfordjournals.jncimonographs.a003469

[7]

Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project protocols B-18 and B-27. J Clin Oncol. 2008;26(5):778–85. 10.1200/jco.2007.15.0235

[8]

Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy

Norikazu Masuda, Shoichiro Ohtani, Young-Hyuck Im et al.

New England Journal of Medicine 2017 10.1056/nejmoa1612645

[9]

von Minckwitz G, Huang C-S, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380(7):617–28. 10.1056/nejmoa1814017

[10]

Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline

Larissa A. Korde, Mark R. Somerfield, Lisa Anne Carey et al.

Journal of Clinical Oncology 2021 10.1200/jco.20.03399

[11]

Pilewskie M, Zabor EC, Mamtani A, Barrio AV, Stempel M, Morrow M. The optimal treatment plan to avoid axillary lymph node dissection in early-stage breast cancer patients differs by surgical strategy and tumor subtype. Ann Surg Oncol. 2017;24(12):3527–33. 10.1245/s10434-017-6016-y

[12]

Kim KII, Lee KH, Kim TR, Chun YS, Lee TH, Park HK. Ki-67 as a predictor of response to neoadjuvant chemotherapy in breast cancer patients. J Breast Cancer. 2014;17(1):40–6. 10.4048/jbc.2014.17.1.40

[13]

Jain P, Doval DC, Batra U, et al. Ki-67 labeling index as a predictor of response to neoadjuvant chemotherapy in breast cancer. Jpn J Clin Oncol. 2019;49(4):329–38. 10.1093/jjco/hyz012

[14]

Kalinsky K, Barlow WE, Gralow JR, et al. 21-Gene assay to inform chemotherapy benefit in node-positive breast cancer. N Engl J Med. 2021;385(25):2336–47. 10.1056/nejmoa2108873

[15]

Sparano JA, Gray RJ, Makower DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018;379(2):111–21. 10.1056/nejmoa1804710

[16]

FDA Approves Abemaciclib with Endocrine Therapy for Early Breast Cancer. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-abemaciclib-endocrine-therapy-early-breast-cancer. Accessed 3 March 2021.

Metrics

28

Citations

16

References

Details

Published: May 15, 2022
Vol/Issue: 29(9)
Pages: 5747-5756
License: View

Authors

Department of Oncology, Mayo Clinic, Rochester, Minnesota

Cite This Article

Judy C. Boughey, Tanya L. Hoskin, Matthew P. Goetz (2022). Neoadjuvant Chemotherapy and Nodal Response Rates in Luminal Breast Cancer: Effects of Age and Tumor Ki67. Annals of Surgical Oncology, 29(9), 5747-5756. https://doi.org/10.1245/s10434-022-11871-z

Neoadjuvant Chemotherapy and Nodal Response Rates in Luminal Breast Cancer: Effects of Age and Tumor Ki67

You May Also Like